Measuring changes in blood levels of two proteins — neurofilament light chain (NfL) and calprotectin (CLP) — may show how…
Patricia Inacio, PhD
Science Writer
Patrícia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. Her expertise started in cell biology, later extending to stem cells and patient-derived cancer organoids at the University of Cambridge, UK. She was selected to an international PhD program, was the recipient of several fellowships to conduct her PhD studies in Portugal and the U.S., and has been an invited speaker across international conferences.
Education
- PhD in Cell Biology, University Nova de Lisboa, Portugal, 2013
- MSc in Biology, 2007
Published Works
- van Tienderen GS, (…), Inacio, P. et al, Cancer Cell. 2022 Mar 14;40(3):226-230.
- Inacio, P. et al, Gut. 2019 Dec;68(12):2228-2237.
- Inacio, P. et al, EMBO Rep. 2015 Aug;16(8):955-64.
- Pinheiro, H (…), Inacio, P. et al, Hum Mol Genet. 2010 Mar 1;19(5):943-52.
Professional Accomplishments
- 2012, Scholarship from Luso-American Development Foundation (Portugal/USA) to perform research at Columbia University, New York
- 2007, Winner of the 1st prize of “Grant Proposal” Final Exercise of Gulbenkian PhD Program
- 2007, PhD Scholarship from Fundação para a Ciência e Tecnologia (Portugal)
- 2007, Selected for the International Gulbenkian PhD Program, at Instituto Gulbenkian de Ciência (IGC), Lisbon, Portugal
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
Black patients with generalized myasthenia gravis (gMG) face significantly higher risks of exacerbations compared with their white counterparts, according…
Rituximab may be safe and effective in treating women with myasthenia gravis (MG) that’s driven by antibodies that target muscle-specific…
People with myasthenia gravis (MG) face a mean annual healthcare cost of nearly $16,000, according to a survey of…
A man with a 16-year history of hard-to-treat generalized myasthenia gravis finally saw his disease successfully managed with Soliris…
The China National Food and Drug Administration has accepted and placed under priority review an application from Remegen seeking approval…
Among people with myasthenia gravis (MG), the degree of daily activity impairment is greater for those with more…
Intravenous (into-the-vein) treatment with Argenx’s Vyvgart (efgartigimod alfa) resolved a myasthenic crisis — a life-threatening complication…
Adolescent girls with juvenile myasthenia gravis (JMG) were more likely to have enlarged thymus glands than younger girls and…
The incidence and prevalence of myasthenia gravis (MG) among the population in France are higher than reported for other…